Aplicación del gel de alendronato al 1 % como coadyuvante en la terapia periodontal
Article Sidebar
Main Article Content
Abstract
Periodontitis is one of the most common conditions that affect the oral cavity, whose most frequent treatment technique is scraping and root planing. However, according to several studies, this technique is considered insufficient for the treatment of periodontitis, so the application of 1 % alendronate for its effect of inhibiting the production of interleukin-1α (IL), IL-6 and TNF and help new bone formation. Its effect orally shows us an encouraging result of bone regeneration, as shown in this study, but also several studies mentioned in this work show a better result applying it in the form of a 1 % gel and locally as an adjuvant to the mechanical therapy. Conclusion: alendronate 1 %, according to the literature consulted, shows promising results in a local application.
Downloads
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
Quesada Llanto IM. Prevalencia de la enfermedad periodontal en pacientes atendidos en la Universidad Peruana Los Andes 2016. Universidad Peruana Los Andes; 2018. Disponible en: http://repositorio.upla.edu.pe/handle/UPLA/327
Giger E V., Castagner B. Biomedical applications of bisphosphonates. Vol. 167, Journal of Controlled Release. 2013. p. 175-88. DOI: https://doi.org/10.1016/j.jconrel.2013.01.032
Tavares SJ da S, Menezes AD. Uso dos bifosfonatos como coadjuvantes na terapia periodontal – revisão de literatura. Rev Interfaces Saúde. 2017;4(12):41-50.
Sheokand V, Chadha VS. The comparative evaluation of 1 % alendronate gel as local drug delivery system in chronic periodontitis in smokers and non smokers: Randomized clinical trial. J Oral Biol Craniofacial Res. 2019; 9(2):198-203. DOI: https://doi.org/10.1016/j.jobcr.2018.05.006
Ipshita S, Kurian IG. One percent alendronate and aloe vera gel local host modulating agents in chronic periodontitis patients with class II furcation defects: A randomized, controlled clinical trial. J Investig Clin Dent. 2018; 9(3):e12334. Disponible en: https://onlinelibrary.wiley.com/doi/abs/10.1111/jicd.12334 DOI: https://doi.org/10.1111/jicd.12334
Akram Z, Abduljabbar T. Efficacy of bisphosphonate as an adjunct to nonsurgical periodontal therapy in the management of periodontal disease: a systematic review. Vol. 83, British Journal of Clinical Pharmacology. 2017. Disponible en: https://pubmed.ncbi.nlm.nih.gov/27718252/ DOI: https://doi.org/10.1111/bcp.13147
Sharma A, Pradeep AR. Clinical Efficacy of 1 % Alendronate Gel as a Local Drug Delivery System in the Treatment of Chronic Periodontitis: A Randomized, Controlled Clinical Trial. J Periodontol. 2012; 83(1):11-8. Disponible en: http://doi.wiley.com/10.1902/jop.2011.110091 DOI: https://doi.org/10.1902/jop.2011.110091
Gait MT, Fontana S. Efecto del alendronato sobre la remodelación del tejido óseo. Estudio experimental. claves en Odontol. 2010;(68):9-19.
Silva RAB, Sousa‐Pereira AP. Alendronate inhibits osteocyte apoptosis and inflammation via IL ‐6, inhibiting bone resorption in periapical lesions of ovariectomized rats. Int Endod J. 2020; 53(1):84-96. Disponible en: https://onlinelibrary.wiley.com/doi/abs/10.1111/iej.13206 DOI: https://doi.org/10.1111/iej.13206
Lane N, Armitage GC. Bisphosphonate therapy improves the outcome of conventional periodontal treatment: results of a 12-month, randomized, placebo-controlled study. J Periodontol. 2005; 76(7):1113-22. Disponible en: https://pubmed.ncbi.nlm.nih.gov/16018754/ DOI: https://doi.org/10.1902/jop.2005.76.7.1113
Rocha ML, Malacara JM. Effect of alendronate on periodontal disease in postmenopausal women: a randomized placebo-controlled trial. J Periodontol. 2004; 75(12):1579-85. Disponible en: https://pubmed.ncbi.nlm.nih.gov/15732857/ DOI: https://doi.org/10.1902/jop.2004.75.12.1579
Rocha M, Nava LE. Clinical and radiological improvement of periodontal disease in patients with type 2 diabetes mellitus treated with alendronate: a randomized, placebo-controlled trial. J Periodontol. 2001; 72(2):204-9. Disponible en: https://pubmed.ncbi.nlm.nih.gov/11288794/ DOI: https://doi.org/10.1902/jop.2001.72.2.204
Sharma A, Pradeep AR. Clinical efficacy of 1 % alendronate gel in adjunct to mechanotherapy in the treatment of aggressive periodontitis: a randomized controlled clinical trial. J Periodontol. 2012; 83(1):19-26. Disponible en: http://doi.wiley.com/10.1902/jop.2011.110206 DOI: https://doi.org/10.1902/jop.2011.110206
Dutra BC, Oliveira AMSD. Effect of 1 % sodium alendronate in the non-surgical treatment of periodontal intraosseous defects: A 6-month clinical trial. J Appl Oral Sci. 2017;25(3):310-7. DOI: https://doi.org/10.1590/1678-7757-2016-0252
Pradeep AR, Kumari M. 1 % Alendronate gel as local drug delivery in the treatment of class ii furcation defects: a randomized controlled clinical trial. J Periodontol; 84(3):307-15. Disponible en: http://doi.wiley.com/10.1902/jop.2012.110729 DOI: https://doi.org/10.1902/jop.2012.110729
Sharma A, Raman A, Pradeep AR. Role of 1 % alendronate gel as adjunct to mechanical therapy in the treatment of chronic periodontitis among smokers. J Appl Oral Sci. 2017; 25(3):243-9. Disponible en: https://pubmed.ncbi.nlm.nih.gov/28678942/ DOI: https://doi.org/10.1590/1678-7757-2016-0201
Pradeep AR, Sharma A. Local drug delivery of alendronate gel for the treatment of patients with chronic periodontitis with diabetes mellitus: a double-masked controlled clinical trial. J Periodontol. 2012; 83(10):1322-8. Disponible en: http://doi.wiley.com/10.1902/jop.2012.110292 DOI: https://doi.org/10.1902/jop.2012.110292
Pradeep AR, Kanoriya D. Chatterjee A. Comparative evaluation of subgingivally delivered 1% alendronate versus 1.2 % atorvastatin gel in treatment of chronic periodontitis: a randomized placebo-controlled clinical trial. J Investig Clin Dent. 2017; 8(3):e12215. Disponible en: http://doi.wiley.com/10.1111/jicd.12215 DOI: https://doi.org/10.1111/jicd.12215
Wanikar I, Rathod S. Clinico-radiographic evaluation of 1 % alendronate gel as an adjunct and smart blood derivative platelet rich fibrin in grade II furcation defects. J Periodontol. 2019; 90(1):52-60. Disponible en: http://doi.wiley.com/10.1002/JPER.18-0146 DOI: https://doi.org/10.1002/JPER.18-0146
Kanoriya D, Pradeep AR. Mandibular degree ii furcation defects treatment with platelet-rich fibrin and 1% alendronate gel combination: a randomized controlled clinical trial. J Periodontol. 2017 (3):250-8. Disponible en: http://doi.wiley.com/10.1902/jop.2016.160269 DOI: https://doi.org/10.1902/jop.2016.160269
Li F, Jiang P, Pan J. Synergistic application of platelet-rich fibrin and 1 % alendronate in periodontal bone regeneration: A meta-analysis. Biomed Res Int. 2019; Disponible en: https://doi.org/10.1155/2019/9148183 DOI: https://doi.org/10.1155/2019/9148183
Melo MD. Osteonecrosis of the jaws in patients with a history of receiving bisphosphonate therapy: Strategies for prevention and early recognition. J Am Dent Assoc. 2005. (12):1675-81. DOI: https://doi.org/10.14219/jada.archive.2005.0110
Marx RE, Sawatari Y. Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg. 2005. 63(11):1567-75. DOI: https://doi.org/10.1016/j.joms.2005.07.010
Estilo CL, Van Poznak CH. Osteonecrosis of the maxilla and mandible in patients with advanced cancer treated with bisphosphonate therapy. Oncologist. 2008;13(8):911-20. DOI: https://doi.org/10.1634/theoncologist.2008-0091
Durie BG, Katz M. Osteonecrosis of the jaw and bisphosphonates. N Engl J Med 2005; 353:99-102. DOI: https://doi.org/10.1056/NEJM200507073530120